Abstract 3838
Background
SB3 has been approved by the European Commission as a biosimilar of reference trastuzumab (TRZ). Equivalence for efficacy between SB3 and TRZ based on breast pathologic complete response (bpCR) rates has been demonstrated and previously reported.1 Here we report results of subgroup analyses of efficacy by baseline disease characteristics and demographics.
Methods
Patients received either SB3 or TRZ for 8 cycles concurrently given with chemotherapy (docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide). Then patients underwent surgery followed by 10 cycles of SB3 or TRZ. The primary endpoint was bpCR rate. Subgroup analyses of bpCR rate, total pathologic complete response (tpCR) rate, and overall response rate (ORR) by region, age, ethnicity, hormone receptor status, breast cancer type, and menopausal status was performed.
Results
800 patients (SB3, n = 402; TRZ, n = 398) were included in the per-protocol set (PPS). The bpCR rates were 51.7% for SB3 and 42.0% for TRZ with adjusted difference of 10.70% (95% CI, 4.13, 17.26). Subgroup analysis results are provided in the table. A trend of favourable efficacy of SB3 compared to TRZ was maintained in most of subgroup analyses. Similar trends were observed in the subgroup analysis of tpCR rate and ORR. Table: bpCR rates by baseline demographics and disease characteristics.Table: 217P
| SB3 n/n’ (%) | TRZ n/n’ (%) | Adjusted difference (%) (SB3-TRZ, 95% CI) | |
|---|---|---|---|
| Region | |||
| Europe | 53/108 (49.1) | 44/98 (44.9) | 3.44 (-9.63, 16.51) |
| Non-Europe | 155/294 (52.7) | 123/300 (41.0) | 13.18 (5.59, 20.77) |
| Age | |||
| Age <45 | 59/121 (48.8) | 48/119 (40.3) | 9.20 (-3.08, 21.48) |
| Age ≥45 | 149/281 (53.0) | 119/279 (42.7) | 11.51 (3.76, 19.26) |
| Ethnicity | |||
| Asian | 68/124 (54.8) | 51/124 (41.1) | 15.52 (4.27, 26.78) |
| White | 135/269 (50.2) | 112/264 (42.4) | 8.45 (0.28, 16.62) |
| Hormone receptor status | |||
| ER and/or PR positive | 119/254 (46.9) | 78/230 (33.9) | 12.87 (4.45, 21.28) |
| ER and PR negative | 89/148 (60.1) | 89/168 (53.0) | 7.34 (-3.14, 17.83) |
| Breast cancer type | |||
| Operable | 120/241 (49.8) | 97/238 (40.8) | 10.14 (1.44, 18.85) |
| Locally advanced | 88/161 (54.7) | 70/160 (43.8) | 11.53 (1.58, 21.48) |
| Menopausal status | |||
| Yes | 105/198 (53.0) | 92/198 (46.5) | 7.65 (-1.33, 16.64) |
| No | 103/204 (50.5) | 75/200 (37.5) | 12.97 (3.81, 22.14) |
CI, confidence interval; ER, oestrogen receptor; PR, progesterone receptor; n, number of patients achieving bpCR; n’, number of patients with available assessment results.
Conclusions
Subgroup analysis results of bpCR, tpCR, and ORR showed a tendency of favourable efficacy in SB3 compared to TRZ, which were consistent with the overall bpCR analysis result. Reference: 1. Pivot X et al. J Clin Oncol. 2018; 36:968-74.
Clinical trial identification
EudraCT: 2013-004172-35.
Legal entity responsible for the study
Samsung Bioepis Co., Ltd.
Funding
Samsung Bioepis Co., Ltd.
Editorial Acknowledgement
Disclosure
J. Cortes Castan: Honoraria: Roche, Novartis, Eisai, Celgene, Pfizer; Consulting/advisor: Roche, Celgene, Aztrazeneca, Cellestia Biotech, Biothera, Merus. X. Pivot: Principle investor: phase III study of SB3; Consultant and honoraria: Samsung Bioepis. G. Curigliano: Fee for a seminar on the abstract. S. Song, Y.C. Yoon: Employment: Samsung Bioepis. All other authors have declared no conflicts of interest.
Resources from the same session
2069 - The concordance with antiemetic guideline for pediatric, adolescent and young adult patients with cancer using a large-scale administrative database.
Presenter: Seiko Bun
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2740 - Effectiveness of surgical glove compression therapy as a prophylactic method against nab-Paclitaxel induced peripheral neuropathy
Presenter: Shigeru Tsuyuki
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2229 - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)
Presenter: Hubert Piessevaux
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4155 - Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)
Presenter: Antony Mersiades
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2473 - Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients
Presenter: Jerome Martin-Babau
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3450 - Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth?
Presenter: Aurore Vozy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2917 - Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey
Presenter: Jean-Francois Morere
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2920 - Benefits of physical activity and sport integrated into the care pathway of oncology patient
Presenter: Laurence Vanlemmens
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5334 - Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study
Presenter: Quan Tran
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
6108 - Quality of life, late effects, and related clinical factors among Korean colorectal cancer survivors
Presenter: Ji Soo Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract